Jorge Boán Pérez

Dr. Jorge Boán Pérez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
LCLaura Corbella
Laura Corbella
JPJorge Boán Pérez
Jorge Boán Pérez
RSRafael San-Juan
Rafael San-Juan
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
OCOctavio Carretero
Octavio Carretero
JAJose Maria Aguado
Jose Maria Aguado

17 January 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
IRIsabel Rodríguez-Goncer
Isabel Rodríguez-Goncer
JPJorge Boán Pérez
Jorge Boán Pérez
RCRiansares Carrero-Arribas
Riansares Carrero-Arribas
JPJosé María Sanchez Pina
José María Sanchez Pina
MLManuel Lizasoaín
Manuel Lizasoaín
MCMaría Calbacho
María Calbacho
Background: Breakthrough invasive mold infections (bIMIs) are life-threatening complications in hematologic cases. Most previous studies in this field covered the whole spectrum of fungal pathogens, including yeasts, and antifungal agents. Methods: We conducted a retrospective study including all hematologic cases of patients diagnosed with a bIMI while receiving a mold-active antifungal agent at our center between January 2017 and June 2022. Results: Overall 37 patients were diagnosed with bIMI: 6 (16.2%) proven, 18 (48.6%) probable, and 13 (35.1%) possible. The highest incidence rate was found for micafungin (1.31 bIMI episodes per 1000 treatment-days), although with no significant differences across antifungal agents. Most patients (90.9%) for whom therapeutic drug monitoring was performed exhibited adequate through levels. Ten (27.0%) patients had undergone allogeneic hematopoietic stem cell transplantation. Aspergillus species was the most common pathogen in cases with microbiological identification. Regarding risk factors, 67.6% had severe neutropenia at diagnosis and 40.5% had received high-intensity chemotherapy. Rates of clinical response and attributable mortality by day +30 were 64.9% and 23.3%, respectively. Poorer performance status, higher Charlson Comorbidity index, older age, and higher C-reactive protein by day +7 were associated with 30-day attributable mortality. Conclusions: Aspergillus was the predominant pathogen in our cohort of bIMIs, with a significant proportion of episodes occurring despite adequate triazole levels. Thirty-day attributable mortality was lower than previously reported. Poorer performance status, higher comorbidity burden, and older age had a relevant role in the outcome of bIMI.

27 May 2025 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
JIJavier Iglesias-Varea
Javier Iglesias-Varea
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
LDLaura Domínguez
Laura Domínguez
JPJorge Boán Pérez
Jorge Boán Pérez
EAEduardo Aparicio-Minguijón
Eduardo Aparicio-Minguijón
FLFrancisco Lopez-Medrano
Francisco Lopez-Medrano
Introducción: La endocarditis infecciosa (EI) es una entidad compleja asociada con una elevada morbimortalidad. La creación de equipos multidisciplinares (endocarditis team) ha demostrado mejorar su manejo y pronóstico. Analizamos el impacto de la implantación formal de un comité multidisciplinar de EI (coEI) en un hospital de tercer nivel. Métodos: Estudio unicéntrico cuasiexperimental con comparación de dos períodos: previo (2010-2015) y posterior a la implementación del coEI (2017-2021). El coEI se reunió semanalmente (y a demanda cuando fue necesario) para la toma de decisiones sobre el abordaje médico-quirúrgico en pacientes con EI definida o posible, aplicando un protocolo basado en guías internacionales. Resultados: Incluimos 92 y 97 pacientes en los períodos pre- y posintervención. Las características demográficas, factores predisponentes y tipo de EI fueron similares. No hubo diferencias entre los períodos pre- y posintervención en la proporción de pacientes con indicación sometidos a cirugía (30,2 % versus 39,1 %, respectivamente; P = 0,317) o en la mortalidad intrahospitalaria (27,2 % versus 34,0 %; P = 0,308) ni al año (32,6 % versus 45,4 %; P = 0,073). La mediana (rango interquartílico) de días desde el diagnóstico hasta la intervención quirúrgica se redujo en el período posintervención (11,5 [6,3 – 25,3]) versus 7 [3 – 10]; P = 0,026). El diagnóstico de fenómenos embólicos fue más frecuente en este período (46,7 % versus 58,8 %; P = 0,098). Conclusiones: Si bien no observamos un impacto significativo en la mortalidad de los pacientes con EI definitiva tras la implantación de un endocarditis team, apreciamos una tendencia favorable en indicadores intermedios de calidad asistencial.

20 February 2026 in Mycoses
Verified
Journal Article
Open access
JPJorge Boán Pérez
Jorge Boán Pérez
EAEduardo Aparicio‐Minguijón
Eduardo Aparicio‐Minguijón
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
MAMaría Asunción Pérez‐Jacoiste Asín
María Asunción Pérez‐Jacoiste Asín
IRIsabel Rodríguez‐Goncer
Isabel Rodríguez‐Goncer
JAJose Maria Aguado
Jose Maria Aguado
Background: Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings. Objectives: We aimed to describe our real‐world experience with rezafungin for the treatment of invasive fungal disease (IFD). Patients: A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted. Results: We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical‐site and intra‐abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole‐resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug–drug interactions with triazoles (15.4%). No patient received rezafungin as a first‐line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow‐up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0–5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment‐emergent adverse events. Conclusions: Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep‐seated candidiasis.

29 November 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JPJorge Boán Pérez
Jorge Boán Pérez
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
EAEduardo Aparicio-Minguijón
Eduardo Aparicio-Minguijón
JAJose Maria Aguado
Jose Maria Aguado
Mucormycosis is an uncommon but life-threatening invasive fungal infection caused by molds of the order Mucorales, whose incidence has increased among solid organ transplant (SOT) recipients in recent years. Profound immunosuppression (particularly high-dose corticosteroids), T-cell-depleting therapies, diabetes mellitus, and previous episodes of graft rejection are the main predisposing conditions. This narrative review summarizes the current evidence on epidemiology, pathogenesis, risk factors, clinical presentation, diagnostic strategies, and treatment outcomes of mucormycosis in the SOT population. Pulmonary and rhino-orbital-cerebral infections are the predominant clinical forms, often characterized by rapid angioinvasive progression and mortality rates exceeding 45%. Early diagnosis remains challenging due to nonspecific clinical manifestations and the limited sensitivity of conventional diagnostic tools, although molecular techniques such as the detection of circulating Mucorales DNA in blood and metagenomic next-generation sequencing are promising. Liposomal amphotericin B remains the first-line therapy, ideally associated to surgical debridement and reduction in immunosuppression, while broad-spectrum triazoles (isavuconazole and posaconazole) represent alternative or salvage options. Despite recent advances in diagnostic methods and antifungal therapy, the prognosis of post-transplant mucormycosis remains poor, underscoring the need for multidisciplinary management and collaborative studies to inform the clinical management in this high-risk population.

9 March 2026 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
RSRafael San-Juan
Rafael San-Juan
JOJulia Origüen
Julia Origüen
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
KCKaren Campion
Karen Campion
JSJose Tiago Silva
Jose Tiago Silva
JAJose Maria Aguado
Jose Maria Aguado
Background: Recurrence of Clostridioides difficile infection (CDI) is frequent, particularly in patients requiring subsequent systemic antibiotics. Observational studies suggest that secondary prophylaxis with oral vancomycin (SPV) may reduce recurrence risk, but randomized evidence remains scarce. Methods: PREVAN (NCT05320068) was a phase III, double-blind, placebo-controlled randomized clinical trial conducted at a tertiary hospital in Spain. Adults with documented CDI within the previous 180 days who required hospitalization and systemic antibiotics were randomized (2:1) to receive oral vancomycin (125 mg every 6 h) or placebo for 10 days, stratified by type of index CDI episode. Primary endpoints were CDI recurrence within 60 days after end of therapy and CDI recurrence-free survival. Results: Twenty-one patients were enrolled (14 SPV; 7 placebo). Mean age was 73.5 years and 76.7% had malignancy and/or immunosuppression. CDI recurrence occurred in 5 patients (23.8%): 2 (14.3%) in the SPV group and 3 (42.9%) in the placebo group (P = 0.30). CDI recurrence-free survival at 60 days was 83% (95% CI 48–95) with SPV versus 42% (95% CI 6–77) with placebo (log-rank P = 0.09). No treatment-related serious adverse events were observed; one mild diarrhoeal event occurred in a placebo-treated patient. Conclusions: In high-risk patients with recent CDI requiring systemic antibiotics, SPV appeared safe and was associated with a clinically relevant reduction in recurrence, although the trial was underpowered. These findings support further adequately powered randomized studies to define the role of SPV in preventing CDI recurrence.